Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial.
J Investig Med High Impact Case Rep
; 10: 23247096221129470, 2022.
Article
in En
| MEDLINE
| ID: mdl-36541195
Full text:
1
Database:
MEDLINE
Main subject:
Carcinoma, Hepatocellular
/
Liver Neoplasms
Limits:
Humans
Language:
En
Year:
2022
Type:
Article